Report: More Than 900 Medicines Are in Testing To Combat Diseases of Aging
> Read More

Report: Helping One Patient at a Time - A Report on West Virginia's Partnership for Prescription Assistance Program
> Read More



> Impact on the Economy
> Breakthrough Medicines
> Medicare Drug Plan
> Prescription Assistance for WV
> Dangers of Government Price Controls
> Research and Development
> Direct-to-Consumer Ads

Introducing WVRx.info, a new online clearinghouse of information about PhRMA’s commitment to improving access to medicines for all West Virginians.
> Learn more


> Learn more about the Pharmaceutical Research and Manufacturers of America.


> Click here to get help paying for your medicines.

 
 
Government Price Controls: Bad Rx for Patients

In many foreign countries, the government pays for most healthcare services, and imposes government price controls on prescription medicines in an effort to reduce total health spending. Studies show that these price controls can have a negative impact on pharmaceutical innovation and patient access to life-saving medications.

Click here to learn more about why price controls are bad for patients.


More About Price Controls:

  • Report: A Primer on Price Controls
    According to a new report, politicians are once again flirting with price controls. But price controls actually hurt low-income people because they keep prices artificially high, plus they stifle competition and destroy innovation. > Read more


  • Department of Health & Human Services – Competition, Innovation and Pricing for Modern Medicines
    Government actions affect prices, prices affect investment, investment affects innovation, and innovation affects health. The more free competition there is in the pharmaceutical and medical device market, the more innovation the world will enjoy. > Read more


  • Guaranteed Future Pain and Suffering: The Recent Research on Drug Price Controls
    by Derek Hunter, Heritage Foundation, November 3, 2005.
    Recent research shows that price controls would lead to less research and development in the pharmaceutical industry, fewer new prescription drugs, and the reduced availability of prescription drugs. > Read more


  • U.S. Department of Commerce Report on Foreign Price Controls
    > Read more


  • U.S. Senate Testimony of Under Secretary for International Trade on Foreign Price Controls
    > Read more